구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous NK cell therapy (Autologous NK cell therapy) Shenzhen Hornetcorn Bio-technology…·NK Cell Mediated Immunity 47 trials |
|---|---|
Overview Program | Autologous NK cell therapy |
Overview Company | Shenzhen Hornetcorn Bio-technology Company, LTD |
Overview Modality | CGT |
Overview Target | NK Cell Mediated Immunity |
Overview Indication | NK Cell Mediated Immunity; Endometriosis |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy (ART) and evade immune clearance |
MoA Mechanism | targeting both CAR antigen |
MoA Biomarker | biomarker of disease biology |
PK/PD Species | Mouse, vivo MPM xenograft |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, vivo MPM xenograft |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.. To explore the feasibility and safety of natural killer (NK) cell therapy in HCC, we performed a prospective, open-label, phase I trial to evaluate the synergistic effect of locoregional high-dose autologous NK cel… |
Toxicology CRS | 83% |
Clinical Safety signal | A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.. To explore the feasibility and safety of natural killer (NK) cell therapy in HCC, we performed a prospective, open-label, phase I trial to evaluate the synergistic effect of locoregional high-dose autologous NK cel… |
Clinical Result source | ClinicalTrials.gov NCT00062868 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT00062868 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous NK cell therapy (Autologous NK cell therapy) Shenzhen Hornetcorn Bio-technology…·NK Cell Mediated Immunity 47 trials |
|---|---|
Overview Program | Autologous NK cell therapy |
Overview Company | Shenzhen Hornetcorn Bio-technology Company, LTD |
Overview Modality | CGT |
Overview Target | NK Cell Mediated Immunity |
Overview Indication | NK Cell Mediated Immunity; Endometriosis |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy (ART) and evade immune clearance |
MoA Mechanism | targeting both CAR antigen |
MoA Biomarker | biomarker of disease biology |
PK/PD Species | Mouse, vivo MPM xenograft |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, vivo MPM xenograft |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.. To explore the feasibility and safety of natural killer (NK) cell therapy in HCC, we performed a prospective, open-label, phase I trial to evaluate the synergistic effect of locoregional high-dose autologous NK cel… |
Toxicology CRS | 83% |
Clinical Safety signal | A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.. To explore the feasibility and safety of natural killer (NK) cell therapy in HCC, we performed a prospective, open-label, phase I trial to evaluate the synergistic effect of locoregional high-dose autologous NK cel… |
Clinical Result source | ClinicalTrials.gov NCT00062868 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT00062868 |
추천 비교
추천 비교